P16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary

Head and Neck

Volumn 36, Issue 12, 2014, Pages 1677-1684

  Keller, Lanea M ^a   Galloway, Thomas J ^a   Holdbrook, Thomas ^a   Ruth, Karen ^a   Yang, Donghua ^a   Dubyk, Cara ^a   Flieder, Douglas ^a   Lango, Miriam N ^a   Mehra, Ranee ^a   Burtness, Barbara ^a   Ridge, John A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Concurrent chemotherapy; Extracapsular extension (ECE); Human papillomavirus (HPV); Tissue microarray; Unknown primary

Indexed keywords

AURORA A KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P16; PROTEIN P53; SURVIVIN; P16 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOFLUORESCENCE TEST; LYMPH NODE DISSECTION; MALE; NECK DISSECTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; SMOKING; STATISTICAL SIGNIFICANCE; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; WART VIRUS; AGE; HEAD AND NECK TUMOR; METABOLISM; MORTALITY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL;

AGE FACTORS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS, UNKNOWN PRIMARY; PAPILLOMAVIRUS INFECTIONS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84912009604     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23514     Document Type: Article

References (33)

1. Issing WJ, Taleban B, Tauber S. Diagnosis and management of carcinoma of unknown primary in the head and neck. Eur Arch Otorhinolaryngol 2003;260: 436-443.
2. Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: A favourable prognosis subset of patients with CUP. Clin Transl Oncol 2009;11: 340-348.
3. Johansen J, Buus S, Loft A, et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck 2008;30: 471-478.
4. Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol 1990;29: 545-550.
5. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. The unknown biology of the unknown primary tumour: A literature review. Ann Oncol 2003;14: 191-196.
6. Cianchetti M, Mancuso AA, Amdur RJ, et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope 2009;119: 2348-2354.
7. Wallace A, Richards GM, Harari PM, et al. Head and neck squamous cell carcinoma from an unknown primary site. Am J Otolaryngol 2011;32: 286-290.
8. Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: Cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 2001;50: 727-733.
9. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363: 24-35.
10. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100: 261-269.
11. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clinl Oncol 2010;28: 4142-4148.
12. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27: 1992-1998.
13. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16- negative oropharyngeal cancer. J Clin Oncol 2012;30: 2102-2111.
14. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29: 4294-4301.
15. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009;27: 6213-6221.
16. Huang DT, Johnson CR, Schmidt-Ullrich R, Grimes M. Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: A comparative study. Int J Radiat Oncol Biol Phys 1992;23: 737-742.
17. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-andneck cancer. Int J Radiat Oncol Biol Phys 2001;51: 571-578.
18. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97: 1808-1815.
19. Pfister DG, Ang KK, Brizel DM, et al. Head and neck cancers. J Natl Compr Cancer Netw 2011;9: 596-650.
20. Chernock RD, El-Mofty SK, Thorstad WL, Parvin CA, Lewis JS Jr. HPVrelated nonkeratinizing squamous cell carcinoma of the oropharynx: Utility of microscopic features in predicting patient outcome. Head Neck Pathol 2009;3: 186-194.
21. Sher DJ, Balboni TA, Haddad RI, et al. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys 2011;80: 1405-1411.
22. Klem ML, Mechalakos JG, Wolden SL, et al. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: Toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys 2008;70: 1100-1107.
23. Fried D, Lehman-Davis M, Hackman T, et al. Dosimetric effect of sparing the primary site for oropharyngeal squamous cell carcinoma after transoral laser microsurgery. Int J Radiat Oncol Biol Phys 2012;84(Supplement): S472.
24. Frank SJ, Rosenthal DI, Petsuksiri J, et al. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010;78: 1005-1010.
25. Karni RJ, Rich JT, Sinha P, Haughey BH. Transoral laser microsurgery: A new approach for unknown primaries of the head and neck. Laryngoscope 2011;121: 1194-1201.
26. Mehta V, Johnson P, Tassler A, et al. A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: A role for transoral robotic surgery. Laryngoscope 2013;123: 146-151.
27. Smith EM, Wang D, Rubenstein LM, Morris WA, Turek LP, Haugen TH. Association between p53 and human papillomavirus in head and neck cancer survival. Cancer Epidemiol Biomarkers Prev 2008;17: 421-427.
28. Haraf DJ, Nodzenski E, Brachman D, et al. Human papillomavirus and p53 in head and neck cancer: Clinical correlates and survival. Clin Cancer Res 1996;2: 755-762.
29. Mehra R, Cai KQ, Zhu F, et al. Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. J Clin Oncol 2010;28(Suppl): 5539.
30. Nijkamp MM, Hoogsteen IJ, Span PN, et al. Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. Radiother Oncol 2011;101: 165-170.
31. Husain H, Psyrri A, Markovic A, et al. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope 2012;122: 2762-2768.
32. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. J Clin Oncol 2008;26: 3138-3146.
33. Kim CH, Koh YW, Han JH, et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck 2010;32: 1655-1664.